As the pharmaceutical-led police state continues to lock up citizens in the United States for a plant, the World Health Organization (WHO), under the direction of the United Nations (UN), is on the precipice of declaring CBD highly beneficial. And, for the first time ever, the United States Food and Drug Administration (FDA) is collaborating with both the WHO and the UN to determine how the WHO should designate CBD under the 1971 Convention on Psychotropic Substances. They want you to help them.
The FDA is now asking for the public’s help to weigh in on the measure to classify CBD appropriately. Those who are interested in keeping CBD not only legal but available to the general public without a prescription (in some states) should immediately comment on an FDA website designated for public comment. According to the FDA’s announcement:
The Food and Drug Administration (FDA) is requesting interested persons to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of 17 drug substances.
Those substances include the following: Ocfentanil, Carfentanil, Pregabalin, Tramadol, Cannabidiol, Ketamine, and Eleven Other Substances.
These comments will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs. WHO will use this information to consider whether to recommend that certain international restrictions be placed on these drugs. This notice requesting comments is required by the Controlled Substances Act (the CSA).
Within the notice, FDA Deputy Commissioner Anna K. Abram acknowledged that “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.”
As Leafly points out, that puts the FDA at odds with the US Drug Enforcement Administration (DEA), which late last year attempted to declare CBD a Schedule I substance. Schedule I drugs, by definition, have “no currently accepted medical use in treatment in the United States.”
As TFTP has reported, CBD is quite harmless but has been shown to help individuals who suffer from chronic pain, epilepsy, Parkinson’s, depression, anxiety, and a myriad of other illnesses.
TFTP spoke to an expert in CBD, John Callahan at AZ CBD Source, to see what he thinks of this move. While the fact that the FDA has declared CBD ‘beneficial’ is certainly noteworthy, there could be other moves at play as well.
Callahan says the move by the FDA might be a result of one pharmaceutical company’s attempt to use the FDA to control the nation’s supply of CBD isolate. That company is called GW Pharmaceuticals (GWPH).
Callahan says GWPH has been rumored to be working with the FDA to retain exclusive control over all the country’s supply of CBD isolate, the purest form of CBD. If that happens, GWPH will be able to take the isolate and craft pharmaceutical-grade prescription pills to be prescribed by a physician for the illnesses which it can treat. In other words, Big Pharma may be making a power-play to take over the supply chain of CBD and using the FDA, the WHO, and the UN to do it.
John says anyone and everyone who can comment about the usefulness of CBD should immediately do so. All of our TFTP readers should express their position about CBD and insist that it be free for anyone and everyone to purchase on the open market.
Because of its incredible track record, saving the lives of countless children, there is no harm in allowing free thinking individuals to decide for themselves if they want to use the naturally-produced substance directly derived from the Hemp plant.
As an aside, GWPH is one of the only pharmaceutical companies in the world offering two branded drugs derived from THC, Sativex and Epidiolex. Both drugs are sold in pharmacies all over the world, but GWPH has yet to receive FDA approval for its drugs to be sold in the US.
To post a positive comment with the FDA about the benefits of CBD, click here. Click on the “Comment Now” button in the top right-hand corner of the page.
You can also contact James Hunter at the FDA’s Center for Drug Evaluation and Research, Controlled Substance Staff in Maryland. He’s at 301-796-3156, and can also be reached at email@example.com.